Search results

1223 results

Sorted by Date . Sort by Relevance

  1. Hypertension in pregnancy

    Everything NICE has said on diagnosing and managing hypertension in pregnancy in an interactive flowchart

  2. EBSCO

    Provider name: EBSCO Lot details Lot 1 - Databases, Aggregated Evidence Resource Summaries, Point of Care (PoC) Tools Lot 2 - Electronic

  3. COVID-19 rapid guideline: dialysis service delivery (NG160)

    The purpose of this guideline is to maximise the safety of patients on dialysis, while protecting staff from infection. It will also enable dialysis services to make the best use of NHS resources and match the capacity of dialysis services to patient needs if these become limited because of the COVID-19 pandemic.

  4. COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders (NG167)

    The purpose of this guideline is to maximise the safety of children and adults with rheumatological autoimmune, inflammatory and metabolic bone disorders during the COVID-19 pandemic, while protecting staff from infection. It also enables services to make the best use of NHS resources.

  5. Public health advisory committees

    Public health advisory committees (PHACs) are the standing committees responsible for the development of our public health guidance. Each committee...

  6. Coronavirus (COVID-19)

    We're supporting the NHS and social care to respond quickly to the challenges of the coronavirus pandemic. We've brought together information that may help you.

  7. Diagnostics guidance static list

    The following published diagnostics assessments have been transferred to the static list. Guidance is moved to the static list following consultation

  8. COVID-19 rapid guideline: children and young people who are immunocompromised (NG174)

    The purpose of this guideline is to maximise the safety of children and young people who are immunocompromised during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  9. Changes to how we work

    Find out about how NICE has changed its methods of producing guidance during the coronavirus pandemic.

  10. Heavy menstrual bleeding

    Everything NICE has said on assessing and managing heavy menstrual bleeding in an interactive flowchart

  11. Sunlight exposure: risks and benefits

    Everything NICE has said on how to communicate the risks and benefits of natural sunlight exposure in an interactive flowchart

  12. MTA process timeline

    These are the main stages in multiple technology appraisals process. Timings are approximate. For a full description of the appraisal process see our

  13. Committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  14. Scholars

    Scholarships are one year opportunities to improve quality of care and contribute to your professional development

  15. STA timeline

    A step-by-step timeline of the process we used to develop single technology appraisals (STA)

  16. Scientific advice

    Advice from NICE to help you generate evidence to inform future NICE evaluations and to enable market access

  17. COVID-19 rapid guideline: chronic kidney disease (NG176)

    The purpose of this guideline is to maximise the safety of adults with chronic kidney disease during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  18. COVID-19 rapid guideline: interstitial lung disease (NG177)

    The purpose of this guideline is to maximise the safety of adults with interstitial lung disease, including idiopathic pulmonary fibrosis and pulmonary sarcoidosis, during the COVID-19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources.

  19. Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)

    Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults

  20. Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months

  21. Brand guidelines

    This is an overview of the NICE brand identity incorporating who we are, what we do, and the values underpinning our work. Who we are NICE is the...

  22. Diagnostics advisory committee

    Our diagnostics assessment recommendations are prepared by an independent advisory committee called the diagnostics advisory committee (DAC). Standing

  23. Pneumonia

    Everything NICE has said on assessing and managing community- and hospital-acquired pneumonia in an interactive flowchart

  24. Past appeals and decisions

    Down to Rejected appeals Cancelled appeals Past appeals TA ID Appraisal short title Appeal hearing date TA111 Alzheimer´s

  25. Topic selection

    How we select the subjects for development into information, advice and guidance

  26. Buy books, journals and databases

    The NICE Electronic and Print Content Framework Agreement - enables the NHS and other health and social care related organisations to buy medical and healthcare related content.

  27. Acute upper gastrointestinal bleeding

    Everything NICE has said on risk assessment and management of acute upper gastrointestinal bleeding in people 16 years and older in an interactive flowchart

  28. Transition from children's to adults' services

    Everything NICE has said on the transition from children's to adults' services for young people in health or social care in an interactive flowchart

  29. Multimorbidity

    Everything NICE has said on optimising care for people with 2 or more long-term health conditions in an interactive flowchart